e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Prognostic factors for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The clinical and pathologic features according to expression of acyl protein thioesterase-1 in stage I non-small cell lung cancer
J. Shin, C. Lee, H. Kim, C. Ahn, Y. Chang (Seoul, Chuncheon, Republic Of Korea)
Source:
Annual Congress 2010 - Prognostic factors for lung cancer
Session:
Prognostic factors for lung cancer
Session type:
Thematic Poster Session
Number:
3216
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Shin, C. Lee, H. Kim, C. Ahn, Y. Chang (Seoul, Chuncheon, Republic Of Korea). The clinical and pathologic features according to expression of acyl protein thioesterase-1 in stage I non-small cell lung cancer. Eur Respir J 2010; 36: Suppl. 54, 3216
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Different expression of miRNA in non-small cell lung cancer according to its clinical stage
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008
The comparison of clinical and pathological stages of the non-small cell lung carcinoma
Source: Eur Respir J 2006; 28: Suppl. 50, 89s
Year: 2006
Assessment of DNA ploidy and proliferating activity changes in neoplasmatic cells according to TNM classification and clinical stages in non-small cell lung cancer (NSCLC) patients during chemotherapy
Source: Eur Respir J 2003; 22: Suppl. 45, 225s
Year: 2003
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 136-142
Year: 2011
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002
A novel biologic classification of non-small cell lung cancer
Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology
Year: 2005
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Source: Eur Respir J 2009; 33: 127-133
Year: 2009
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Comparison of clinic and pathological staging in non-small cell lung cancer
Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology
Year: 2010
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer?
Source: Eur Respir J 2001; 18: Suppl. 33, 232s
Year: 2001
PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer
Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules
Year: 2018
Clinical evaluation of the plasma levels of hTERT and EGFR expression as markers for early detection of non-small cell lung cancer
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept